Lunder M, et al. - Researchers investigated how endothelial function and arterial stiffness parameters in patients with type 1 diabetes mellitus (T1DM) are affected by empagliflozin on top of metformin treatment. This study included 40 patients with T1DM who were randomly assigned to either empagliflozin (25 mg daily), metformin (2,000 mg daily), empagliflozin/metformin (25 mg daily and 2,000 mg daily, respectively), or placebo treatment groups. The investigators observed remarkable improvements in arterial stiffness in patients with T1DM who received empagliflozin on top of metformin treatment vs metformin alone. They noted similarly improved endothelial function across all treatment groups. According to findings, empagliflozin could decrease arterial stiffness, which could support its cardioprotective effects observed in large clinical studies.